Corline Biomedical (Q1 Review): Encouraging signs of commercial acceleration - Redeye

Redeye provides an update following Corline’s Q1 2026 report. We are positive on the sales development, which shows early signs of a sales ramp-up. We maintain a positive view on Corline’s outlook and expect a clearer sales ramp-up in the coming quarters. We have only made minor fine-tuning to our estimates, leaving our fair value range unchanged.

Länk till analysen i sin helhet: https://www.redeye.se/research/1165603/corline-biomedical-q1-review-encouraging-signs-of-commercial-acceleration?utm_source=finwire&utm_medium=RSS